Observations placeholder
Febuxostat and Uloric
Identifier
016797
Type of Spiritual Experience
Number of hallucinations: 11
Background
A description of the experience
Febuxostat (INN; trade names Adenuric in Europe and New Zealand and Uloric in the US) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.
Febuxostat received marketing approval by the European Medicines Agency for Menarini on April 21, 2008 and was approved by the U.S. Food and Drug Administration for Takeda on February 16, 2009
On Dec, 24, 2016 3,605 people reported to have side effects when taking Uloric.
Among them, 72 people (2.0%) have Death
Time on Uloric when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Uloric :
| Female | Male | |
| Death | 29.17% | 70.83% |
Age of people who have Death when taking Uloric :
0-12-910-1920-2930-3940-4950-5960+ Death0.00%0.00%0.00%0.00%0.00%5.56%0.00%94.44%
On Dec, 26, 2016 3,605 people reported to have side effects when taking Uloric.
Among them, 11 people (0.31%) have Hallucination
Time on Uloric when people have Hallucinations :
| n/a |
Gender of people who have Hallucinations when taking Uloric :
| Female | Male | |
| Hallucinations | 100.00% | 0.00% |